LifeArc negotiates exclusive licence deal with Nemysis for oral iron supplement technology
IHAT, a novel synthetic material, is a commercially viable alternative to ferrous salts for iron supplementation.
LifeArc, the medical research charity formerly known as MRC Technology, has negotiated a licence for an oral iron supplement technology with Nemysis. Iron oxo-hydroxide adipate tartrate (IHAT) was developed at the Medical Research Council (MRC) Human Nutrition Research Unit, whose research LifeArc supports to increase the health benefits arising from MRC research. Under the licence Nemysis will develop, manufacture and market the oral iron supplement technology.
Iron deficiency is the most common nutritional deficiency in the world. Children, pre-menopausal women and people with a poor diet such as the elderly, those in the developing world or leading busy lifestyles are most susceptible to iron deficiency and associated iron deficiency anaemia (IDA). Iron deficiency and IDA is estimated to affect 1 billion people worldwide and is one of the top-10 risk factors contributing to the global burden of disease (WHO’s top 10 list for disease cure and prevention).
Current supplements for iron deficiency include ferric compounds which are very poorly absorbed (~2%) and ferrous compounds which are associated with well-recognised toxicity issues that lead to gastrointestinal side effects, poor compliance and additional healthcare costs. IHAT is a novel synthetic material based on the chemistry of natural, digested dietary iron. Due to its low manufacturing cost, near equivalent bioavailability to ferrous salts and increased safety profile, IHAT is a commercially viable alternative to ferrous salts for iron supplementation.
Andrew Farquharson, Executive Director Technology Transfer at LifeArc, said: “There is a major unmet need for new oral iron supplements that offer reduced gastrointestinal side effects and we are delighted to have helped translate this innovative research from the MRC. IHAT is an exciting oral supplement that we hope will soon be available to patients worldwide.”
Mr Danilo Casadei Massari, Chief Executive Officer, Nemysis, said: “This is an exciting time for us all. Nemysis is a newly founded specialty pharmaceutical company that focuses on the research and development of proprietary products with unique safety profiles to address Iron Deficiency/Anaemia and Celiac Disease. We welcome the opportunity to develop up to commercial stage products based on this innovative technology.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance